ROCKVILLE, Md., Dec. 6, 2022 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the publication of a manuscript discussing prostate cancer cell lines derived from African American men for precision medicine. The manuscript, titled “Novel paired normal prostate and prostate cancer model cell systems derived from African American patients,” by Dr. Mira Jung was published in Cancer Research Communications, a journal affiliated with the American Association for Cancer Research (AACR), the premier international cancer research society.
Unique cell cultures were developed by a collaborative effort of Shuttle Pharma and Georgetown University scientists and clinicians in a “Moonshot” project funded by the NIH SBIR program to address prostate cancer health disparities in African American men. Prostate cancer is the most frequently diagnosed solid malignancy in men. African American (AA) men are at greater risk for developing prostate cancer, and experience higher mortality rates, as compared to Caucasian American (CA) men. However, mechanistic studies to understand this health disparity have been limited by the lack of relevant in vitro and in vivo models. There is an urgent need for preclinical cellular models to investigate molecular mechanisms underlying prostate cancer in AA men. By collecting clinical specimens from radical prostatectomies of AA patients, ten paired tumor-derived and normal epithelial cell cultures were established from the same donors and cultivated to extend the growth under “conditional reprogramming (CR).”
“These cells can be used to study basic biological mechanisms of cancer and they can be used for screening drugs or to determine effectiveness of cancer therapeutics,” commented Scott Grindrod, the principal investigator and Laboratory Chief at Shuttle Pharmaceuticals.
Consistent with NIH SBIR funding goals, private companies are encouraged to collaborate with academic institutions to develop and commercialize novel technologies. This research project advances research into prostate cancer health disparities for African American men.
A copy of the publication is available at: https://shuttlepharma.com/wp-content/uploads/2022/12/crc-22-0203.pdf.
Mira Jung, PhD is a Co-Founder & Scientific Director of Shuttle Pharmaceuticals.
Cancer Research Communications is an open access peer-reviewed journal that encompasses the full spectrum of research on cancer. Launched in October 2021, the journal aims to accelerate the pace of discovery and stimulate innovation in cancer science and medicine by providing a venue for rapid open publication of hypotheses, methods, results, data resources, and new knowledge in all the varied disciplines of this quickly evolving field. Basic, translational, clinical, and population-level cancer research advances all fall within the scope of Cancer Research Communications. Articles report novel findings, provide support to previously published results, or present thought-provoking null results.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharmaceuticals is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning the development of our company. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of Shuttle Pharma’s IPO prospectus filed with the SEC on August 31, 2022, and any risk factors set forth in the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 14, 2022, or any other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Shuttle Pharmaceuticals
Anatoly Dritschilo, M.D., CEO
240-403-4212
info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/shuttle-pharmaceuticals-manuscript-published-in-cancer-research-communications-301695219.html
SOURCE Shuttle Pharmaceuticals Holdings, Inc.